J. T. Tibung

Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.

J. Kira, T. Yamamura, M. Subramanyam, 2017, Multiple sclerosis and related disorders.

Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis

J. Kira, T. Yamamura, T. Saida, 2017, Neurological Therapeutics.

Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial

J. Kira, T. Yamamura, D. Steiner, 2016, Neurology and Therapy.